Travere Therapeutics Inc
NASDAQ:TVTX
Travere Therapeutics Inc
NASDAQ:TVTX
Price:
6.26 USD
1.62%
Market Closed
Updated:
May 5, 2024
Travere Therapeutics Inc
Cash from Financing Activities
|
Travere Therapeutics Inc
Cash from Financing Activities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Cash from Financing Activities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Travere Therapeutics Inc
NASDAQ:TVTX
|
Cash from Financing Activities
$218.8m
|
CAGR 3-Years
20%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
22%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Cash from Financing Activities
-$17.2B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-17%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Cash from Financing Activities
-$5.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Cash from Financing Activities
$21B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
23%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Cash from Financing Activities
-$562.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-51%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Cash from Financing Activities
-$1.8B
|
CAGR 3-Years
3%
|
CAGR 5-Years
-88%
|
CAGR 10-Years
N/A
|
See Also
What is Travere Therapeutics Inc's Cash from Financing Activities?
Cash from Financing Activities
218.8m
USD
218.8m
USD
Based on the financial report for Dec 31, 2023, Travere Therapeutics Inc's Cash from Financing Activities amounts to 218.8m USD.
What is Travere Therapeutics Inc's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
22%
22%
Over the last year, the Cash from Financing Activities growth was 86%. The average annual Cash from Financing Activities growth rates for Travere Therapeutics Inc have been 20% over the past three years , -1% over the past five years , and 22% over the past ten years .
You don't have any saved screeners yet
